Relationship between metabolic disorder in polycystic ovary syndrome and zinc α 2 glycoprotein / 中国基层医药

ABSTRACT

Objective:To explore the changes of serum zinc-2 glycoprotein (ZAG) levels in patients with polycystic ovary syndrome (PCOS) with metabolic indicators, and to seek the correlation between metabolic disorders and ZAG in patients with PCOS, so as to provide a basis for the diagnosis and treatment of metabolic disorders in patients with PCOS.Methods:A total of 200 Han PCOS patients admitted to Shenzhen Hospital of Guangzhou University of Traditional Chinese Medicine (Futian) from January 2017 to June 2018 were selected as the observation group, and divided into the group A (BMI ≥ 25kg/m 2) and the group B (BMI <25kg/m 2) according to body mass index(BMI). Meanwhile, 100 healthy Han women who came to the hospital for physical examination during this period were selected as the control group.ZAG, fasting blood glucose (FPG), fasting insulin (FINS), triglyceride (TG), total cholesterol (TC), low-density lipoprotein (LDL), and high-density lipoprotein (HDL) were measured, and the differences among the three groups were compared.After weight control, group A reviewed the above indicators and compared the differences of these indicators before and after weight control. Results:In group A, the FPG, FINS, HOMA-IR, TC, TG, HDL, LDL and ZAG were (5.92±0.51)mmol/L, (19.94±3.15)mIU/L, (5.29±1.19), (5.59±0.49)mmol/L, (2.03±0.35)mmol/L, (0.72±0.21)mmol/L, (3.05±0.43)mmol/L, (35.80±8.12)ng/mL, respectively, which in group B were (5.38±0.62)mmol/L, (15.67±4.59)mIU/L, (3.84±1.45), (4.61±0.65)mmol/L, (1.49±0.35)mmol/L, (1.24±0.40)mmol/L, (2.61±0.40)mmol/L, (45.22±10.27)ng/mL, respectively, which in the control group were (4.77±0.53)mmol/L, (11.66±3.23)mIU/L, (2.52±0.95), (4.59±0.53)mmol/L, (1.39±0.26)mmol/L, (1.40±0.31)mmol/L, (2.50±0.35)mmol/L, (59.15±8.90)ng/mL, respectively, and the differences were statistically significant between group A and group B, between group A and control group, and between group B and control group( F=36.81, 41.04, 44.05, 33.65, 38.61, 39.25, 18.45, 56.88, all P<0.01). After weight control, the FPG, FINS, HOMA-IR, TC, TG, HDL, LDL and ZAG in group A were (5.27±0.54)mmol/L, (15.67±3.16)mIU/L, (3.72±1.06), (4.98±0.45)mmol/L, (1.62±0.30)mmol/L, (1.03±0.25)mmol/L, (2.82±0.43)mmol/L, (43.59±8.20)ng/mL, respectively, and the differences were statistically significant in group A before and after weight control ( t=15.26, 15.67, 17.70, 11.04, 17.61, -9.61, 22.83, -13.79, all P<0.01). The serum ZAG was positively correlated with HDL ( r=0.628, P<0.01), and negatively correlated with BMI ( r=-0.685, P<0.01), HOMA-IR ( r=-0.729, P<0.01), and TC ( r=-0.579, P<0.01). Conclusion:ZAG value is reducedin PCOS patients, with lower level in obesity group, and is positively correlated with HDL, negatively correlated with BMI, HOMA-IR, TC.The metabolism in patients with PCOS can be reflected by ZAG, which has a certain value in diagnosis and treatment of PCOS patients with metabolic disorder, and provides theory basis for further study of the metabolic disorder of PCOS.